印度到2050年将面临11.4万亿美元的糖尿病费用,由于高发病率和护理负担,仅次于美国。 India faces $11.4 trillion in diabetes costs by 2050, second only to the U.S., due to high prevalence and caregiving burdens.

印度在糖尿病相关经济成本方面位居全球第二, 根据一项自然医学研究, 预计到2050年将达到11.4万亿美元, 低于美国16.5万亿美元。 India ranks second globally in diabetes-related economic costs, projected at $11.4 trillion through 2050, behind the U.S. at $16.5 trillion, according to a Nature Medicine study. 这项研究以204个国家的数据为基础,发现非正规护理占负担的近90%,其驱动因素是糖尿病高发病率和长期护理需求。 The research, based on data from 204 countries, finds informal caregiving accounts for nearly 90% of the burden, driven by high diabetes prevalence and long-term care needs. 印度的高成本来自其大量受影响人口,而美国的负担反映了高治疗费用。 India’s high cost stems from its large affected population, while the U.S. burden reflects high treatment expenses. 全世界超过四分之一的糖尿病患者居住在印度, Over a quarter of the world’s diabetics live in India, per a 2024 Lancet study. 这项研究强调,早期发现、普遍筛查和及时治疗是减少健康和经济影响的关键,突出了全球在获得慢性疾病护理方面的不平等。 The study stresses early detection, universal screening, and timely treatment as key to reducing health and economic impacts, highlighting global inequities in chronic disease care access.